{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
FOX04-DRI (FOXO4-D-Retro-Inverso) is an experimental synthetic peptide designed to act as a senolytic, meaning it selectively targets and clears senescent (aging or "zombie") cells.
How It Works
• Targeting Senescent Cells: Senescent cells accumulate with age and release harmful inflammatory signals known as the Senescence-Associated Secretory Phenotype (SASP).
• Disrupting FOXO4 and p53: Normally, the protein FOXO4 binds to the tumor suppressor protein p53 in senescent cells, trapping it and preventing programmed cell death (apoptosis).
• D-Retro-Inverso Design: The peptide uses reversed sequences of D-amino acids to resist quick breakdown in the body and wedge itself between FOXO4 and p53, freeing p53 to trigger apoptosis in the damaged cells while sparing healthy cells.
Research Status
• Preclinical Evidence: Studies in aged mice have shown positive results, such as reduced senescence markers, improved physical function, and better testosterone or vascular health. Detailed academic findings are tracked via resources like PMC and commentary on Fight Aging!.
• No Human Approval: FOX04-DRI is not FDA-approved and has not undergone clinical trials in humans. Its safety, proper dosing, and long-term effects in people remain unknown